Musashino-shi, Tokyo, Japan Clinical Trials

A listing of Musashino-shi, Tokyo, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 414 clinical trials
featured
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.

Center Hospital of the National Center for Global Health and Medicine
 (8.4 away) Contact site
  • 48 views
  • 29 Jul, 2021
  • +83 other locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Tokyo Medical University Hospital /ID# 221540
 (7.3 away) Contact site
  • 226 views
  • 29 Apr, 2021
  • +224 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

FGFR2
primary cancer
metastatic cancer
cancer
Kyorin University Hospital
 (2.4 away) Contact site
  • 173 views
  • 25 Aug, 2021
  • +145 other locations
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder cancer
urothelial carcinoma
bladder carcinoma
metastatic urothelial carcinoma
St. Marianna University School of Medicine HP
 (8.2 away) Contact site
  • 29 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

solid tumor
cancer
metastasis
solid tumors
measurable disease
Keio University Hospital
 (8.8 away) Contact site
  • 46 views
  • 25 Aug, 2021
  • +56 other locations
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in …

neutrophil count
microsatellite instability high
fluoropyrimidine
irinotecan
vegf
The Cancer Institute Hospital Of JFCR
 (5.5 away) Contact site
  • 0 views
  • 13 Feb, 2021
  • +42 other locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

growth factor
carboplatin
epidermal growth factor receptor
measurable disease
lung carcinoma
The Cancer Institute Hospital of JFCR
 (7.3 away) Contact site
  • 1 views
  • 22 Sep, 2021
  • +289 other locations
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week …

Novartis Investigative Site
 (8.1 away) Contact site
  • 0 views
  • 17 Sep, 2021
  • +97 other locations
Study of Ravulizumab in Pediatric Participants With HSCT-TMA

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.

Clinical Trial Site
 (6.9 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +33 other locations
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

This study aims to define the efficacy and safety of inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD).

Viela Bio Investigative Site
 (5.5 away) Contact site
  • 0 views
  • 19 Aug, 2021
  • +85 other locations